France Glioblastoma Multiforme Treatment Market Size & Outlook
Related Markets
France glioblastoma multiforme treatment market highlights
- The France glioblastoma multiforme treatment market generated a revenue of USD 113.8 million in 2024 and is expected to reach USD 257.2 million by 2033.
- The France market is expected to grow at a CAGR of 9.5% from 2025 to 2033.
- In terms of segment, surgery was the largest revenue generating treatment in 2024.
- Tumor Treating Field (TTF) Therapy is the most lucrative treatment segment registering the fastest growth during the forecast period.
Glioblastoma multiforme treatment market data book summary
| Market revenue in 2024 | USD 113.8 million |
| Market revenue in 2033 | USD 257.2 million |
| Growth rate | 9.5% (CAGR from 2025 to 2033) |
| Largest segment | Surgery |
| Fastest growing segment | Tumor Treating Field (TTF) Therapy |
| Historical data | 2021 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Targeted Therapy (Bevacizumab), Tumor Treating Field (TTF) Therapy, Radiation Therapy, Surgery, Chemotherapy |
| Key market players worldwide | Merck & Co Inc, Amgen Inc, Roche, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries, Arbor Pharmaceuticals, Amneal Pharmaceuticals, Karyopharm Therapeutics Inc, Sumitomo Dainippon Pharma Oncology |
Other key industry trends
- In terms of revenue, France accounted for 3.1% of the global glioblastoma multiforme treatment market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Europe, Germany glioblastoma multiforme treatment market is projected to lead the regional market in terms of revenue in 2033.
- France is the fastest growing regional market in Europe and is projected to reach USD 257.2 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Glioblastoma Multiforme Treatment Market Scope
Glioblastoma Multiforme Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Sumitomo Dainippon Pharma Oncology | View profile | 251-500 | Cambridge, Massachusetts, United States, North America | https://www.sdponcology.com/ |
| Amneal Pharmaceuticals | View profile | 5001-10000 | Bridgewater, New Jersey, United States, North America | http://amneal.com/ |
| Arbor Pharmaceuticals | View profile | 501-1000 | Atlanta, Georgia, United States, North America | http://www.arborpharma.com |
| Karyopharm Therapeutics Inc | View profile | 325 | 85 Wells Avenue, 2nd Floor, Newton, MA, United States, 02459 | https://www.karyopharm.com |
| Roche | View profile | 10001+ | Basel, Basel-Stadt, Switzerland, Europe | http://www.roche.com |
| Sun Pharmaceutical Industries | View profile | 10001+ | Mumbai, Maharashtra, India, Asia | http://www.sunpharma.com |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| Amgen Inc | View profile | 26700 | One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 | https://www.amgen.com |
| Teva Pharmaceutical Industries Ltd | View profile | 37851 | 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 | https://www.tevapharm.com |
France glioblastoma multiforme treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to glioblastoma multiforme treatment market will help companies and investors design strategic landscapes.
Surgery was the largest segment with a revenue share of 34.09% in 2024. Horizon Databook has segmented the France glioblastoma multiforme treatment market based on targeted therapy (bevacizumab), tumor treating field (ttf) therapy, radiation therapy, surgery, chemotherapy covering the revenue growth of each sub-segment from 2021 to 2033.
France Glioblastoma Multiforme (GBM) treatment market to reach an estimated value of USD 181.86 million in 2028. France has the second-highest healthcare expenditure in the EU. The pharmaceutical industry of France is progressing within an enormously competitive international environment and a strongly inventive and dynamic context.
Availability of a well qualified/trained staff, high-quality of research, and presence of an adaptable industry that is capable of fulfilling the changing market needs have made France a key player in pharmaceutical space. The French healthcare system is largely financed by government national health insurance, wherein 70% of the healthcare costs and 100% in case of costly or chronic conditions are reimbursed.
The annual incidence of GBM in France is estimated at 3.3 per 100,000 people. Increasing government initiatives to improve diagnosis & treatment of rare diseases, wider access to GBM therapies, and favorable reimbursement policies are anticipated to support the market growth in the country.
Reasons to subscribe to France glioblastoma multiforme treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of France glioblastoma multiforme treatment market databook
-
Our clientele includes a mix of glioblastoma multiforme treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the France glioblastoma multiforme treatment market , including forecasts for subscribers. This country databook contains high-level insights into France glioblastoma multiforme treatment market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
France glioblastoma multiforme treatment gbm market size, by treatment, 2021-2033 (US$M)
France Glioblastoma Multiforme Treatment Market Outlook Share, 2024 & 2033 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
